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Hydrazine  (N2H4) is  a known  genotoxic  impurity  that  typically  needs  to be controlled  down  to  low  ppm
level  in pharmaceutical  development.  Hydrazine,  however,  is a challenging  molecule  to  analyze  using
conventional  analytical  techniques  due  to its  physical  and  chemical  properties  (e.g.  lack  of  chromophore,
absence  of  any  carbon  atom,  low  molecular  weight,  high  polarity  and  volatility).  Additionally,  analy-
sis  in  pharmaceutical  samples  commonly  encounters  signiﬁcant  interference  from  matrix  components
that  greatly  overshadow  the  response  of hydrazine.  This  work  describes  a simple,  accurate  and  sensitive
reversed-phase  liquid  chromatography—UV  derivatization  method  for determination  of  trace  amount
hydrazine  in  pharmaceutical  materials  featuring  three  prominent  strategies  to  address  the  problems
associated  with  hydrazine  analysis.  First, the derivatization  reaction  attaches  chromophores  to  hydrazine,
which  greatly  increases  its sensitivity  by UV–vis  detection.  Secondly,  the  derivatization  reaction  gener-
ates  a lambda  max  that  is  well-shifted  away  from  the  absorption  wavelengths  of pharmaceutical  matrix
interferences.  Thirdly,  from  a separation  standpoint,  the  derivatization  further  removes  matrix  inter-
ference  effects  through  chromatography  by achieving  higher  resolution  of  the  derivative  product  from
the  active  pharmaceutical  ingredient  (API)  and its  related impurities  for accurate  quantitation  for trace
level  of genotoxic  impurities  (GTIs).  2-Hydroxy-1-Naphthalaldehyde  (HNA)  was chosen  as the  deriva-
tizing  reagent,  and  the resulting  hydrazone  product  has  a maximum  UV absorbance  at wavelength  of
406/424  nm which  is in  the  visible  range.  Since  most  drug  substance  and  impurities  have  UV  absorbance
ranging  from  190  to 380 nm, interference  from  the  matrix  was  minimized  and  the  appropriate  selectivity
was  obtained,  the  detection  limit  is 0.25  ppm (0.25 g/g  API).  This  method  was  validated  and  applied  as
a  generic  method  to  determine  hydrazine  for  pharmaceutical  process  control  and drug  material  release.
©  2016  The  Author(s).  Published  by Elsevier  B.V.  This  is an  open  access  article  under  the CC. Introduction
Hydrazine (N2H4) is a small molecule chemical used in the
ormation of indazoles [1,2] (a common moiety of many small
olecule drugs), the Knorr Synthesis [3,4], the Gabriel Synthesis
5], and the Wolff-Kishner reaction [6], of which all are commonly
sed reactions in pharmaceutical drug API processes [1,2,4,7,8].
owever, hydrazine is a known genotoxic impurity (GTI) with
enotoxicity and carcinogenicity. Over the years, regulatory health
gencies have steadily increased the level of scrutiny required for
ontrol of GTIs in drug substance materials, which in turn raises the
ar on requirements for analytical methods to quantify hydrazine
t low ppm levels. According to the recently published addendum
o ICH M7  (R1) in June 2015, hazard assessment data for hydrazine
∗ Corresponding author.
E-mail address: zhang.kelly@gene.com (K. Zhang).
ttp://dx.doi.org/10.1016/j.jpba.2016.04.038
731-7085/© 2016 The Author(s). Published by Elsevier B.V. This is an open access articl
.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
showed it to be mutagenic/genotoxic in vitro and in vivo and pos-
sibly carcinogenic to humans [9], leading hydrazine to a Class 1 GTI
classiﬁcation, which needs be controlled at or below a compound
speciﬁc acceptable limit. In general, most pharmaceutical drug sub-
stances have an acceptable intake of GTI that must be controlled to
a daily dose of 1.5 g per person for long-term treatment, which
corresponds to a theoretical 1:100,000 carcinogenic risk [10]. This
drives the industry to seek sensitive methods to accurately quan-
titate hydrazine in order to control its levels during the synthetic
process and in the ﬁnal drug substance.
Despite the need for accurate hydrazine analysis, hydrazine
quantitation is particularly difﬁcult from an analytical standpoint.
It is highly reactive, which causes unwanted side reactions dur-
ing sample preparation and ultimately leads to inconsistent results
and a high frequency of false positives. Additionally, hydrazine has
neither a chromaphore for UV based detection methods nor an ion-
izable group for sensitive analysis by mass spectrometry. Because
of its lack of carbon atoms, hydrazine is also difﬁcult to analyze by
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Table 1
Derivatization Reaction Screening.
Derivatization Reagent Structure Maxima
Wavelength (nm)
Experimental Outcome
4-Hydroxylbenzaldehyde 340 Promising candidate, the derivatized product was difﬁcult
to  separate from the API matrix components
Naphthalene-2,3-Dicarboxaldehyde 363 Costly reagent and not suited for repeated batch analysis
in large scale quantities
5-Chloro-Salicylaldehyde 365 Chromatography screen showed inadequate resolution
from API peak and matrix components
5-Fluoro-2,3-Thiophenedicarboxaldehyde N/A Chromatography screen showed inadequate resolution
from API peak and matrix components
2-Hydroxy-1-Naphthaldehyde 406 Ideal candidate, simple reactions conditions;
chromatography screen showed high selectivity in
derivatized product
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ame ionization detection (FID) due to low sensitivity issues. Other
ewer technologies such as charged aerosol detection (CAD) have
een explored [11], but the sensitivity is not high enough to detect
ree hydrazine at low levels due to its volatility. As such, deriva-
ization becomes an attractive approach to achieve the necessary
electivity and sensitivity.
There have been many reported methods used to detect and
uantify hydrazine [12–14], most of which use a derivatization
pproach coupled with analytical techniques ranging from GC
15–17], GC–MS [15,18], LC [19–21], LC–MS/MS [22–24], CAD [11],
apillary electrophoresis [25], electrochemical sensing [26–30] and
on chromatography (IC) [31]. The literature has demonstrated
any different applications with a large portion of the reported
iterature focusing on environmental detection of hydrazine from
rinking waters or bioanalytical applications [15,18,23]. In par-
icular, the work done by Oh and associates details a method to
chieve ultra-low limits of detection of hydrazine from drinking
ater samples [23]. Their study assessed an assortment of deriva-
ization agents involving a Schiff base reaction with hydrazine.
aphthalene-2,3-dialdehyde was selected as the derivatization
eagent to react with hydrazine in a 1:1 ratio in a controlled reac-
ion allowing full conversion of the hydrazine into the derivatized
roduct. A fast LC–MS/MS method was then developed to analyze
he derivatized hydrazone product and quantiﬁed using a triple
uadrupole mass spectrometer in SRM to reach part-per-billion
evel limits of detection with suitable accuracy and precision [23].
Hydrazine quantitation in a pharmaceutical setting, however,
oses another very speciﬁc set of challenges due to the inter-
erence from the bulk drug matrix and related substances, and
urrently there is lack of good sensitive methods for the quan-
itation of hydrazine from pharmaceutical compounds. Currently
here is a derivatization-headspace GC–MS approach detecting
ydrazine from complex pharmaceutical samples using acetone
nd deuterated acetone as the derivatization agent [17]. From a
ood manufacturing practice (GMP) standpoint, methods using
V detection are preferred given its prevalent availability in GMP
aboratories as opposed to other detection methods (i.g. mass
pectrometry), especially during method transfer activities across
orldwide different contract manufacturing and research facilities.No reaction observed
Analytical methods must still be sensitive enough to quantitate low
GTI levels of hydrazine in drug samples, but these samples con-
tain enormous levels of matrix interferences stemming from the
active pharmaceutical ingredient (API) itself and its related sub-
stances, which generally constitute about 97–99% (w/w) of the
sample with hydrazine present in the sample at ppm (w/w) levels
by mass. These matrix components are usually UV  absorbing caus-
ing signiﬁcant inferences to hydrazine even when analyzing the
derivatized hydrazone product. Additionally, these matrix compo-
nents factor into the chromatography, as most of these components
are API or API related substances that retain well on reversed-
phase chromatography and potentially coelute with the derivatized
hydrazone product.
The goal of this study is to develop a sensitive, selective, accu-
rate, reproducible and simple method to analyze hydrazine from
pharmaceutical API and intermediates. The strategy to address the
common problems associated with hydrazine analysis (e.g. sen-
sitivity, matrix interferences, and challenging chromatography) is
to use a derivatization reaction approach to meet pharmaceutical
method requirements. Selection of the best derivatization agent
is critical for the success of the method development. The result-
ing derivatized product must give strong UV absorption to satisfy
the high sensitivity needs of a GTI method in the pharmaceutical
industry. Additionally, the UV absorption lambda max  must also
be well-shifted away from the absorption regions of the drug API
and its related substances matrix components, which are typically
strong absorbing around 190–380 nm.  Of course, the derivatization
reaction should be selective to hydrazine and should be optimized
so that there is nearly 100% conversion of hydrazine into the
derivatized hydrazone product to be representative of true sample
hydrazine content. From a separation point of view, the chromatog-
raphy must be developed for high resolution of the derivatized
hydrazone product from the rest of the API and its related impuri-
ties to ensure adequate sensitivity for low level GTI detection. In the
ideal case, the method would elute all the matrix components from
the sample early near the void volume and retain the hydrazine
product of interest for analysis further along in the method. The
method also must consider the fact that the API peak greatly over-
shadows the hydrazine peak, and that peak tailing associated with
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uch an API large peak will obscure the sensitive analysis of adjacent
ow level peaks from hydrazine.
With these strategies in mind, the work from this study
escribes a simple derivatization method for hydrazine analy-
is from different drug substance samples using reversed-phase
PLC-UV. The study conducted a screen of different derivatiza-
ion reactions to identify the best candidate that ﬁts our needs; the
eaction was then optimized to fully convert the hydrazine into a
erivatized hydrazone product. Using the optimized derivatization
eaction, the chromatography was then developed for the hydra-
one product to achieve the resolution requirements needed for
race level GTI analysis. The ﬁnal method was qualiﬁed for speci-
city, accuracy, sensitivity, linearity, and precision. An application
f this analysis was demonstrated using two pharmaceutical mate-
ials with different physicochemical properties.
. Experimental
.1. Compounds and reagents
Hydrazine Monohydrate (>99%), 2-Hydroxy-1-
aphthaldehyde (>99%), 4-Hydroxylbenzaldehyde,
-Fluoro-2,3-Thiophenedicarboxaldehyde, and Triﬂuoroacetic
cid were purchased from Sigma-Aldrich (St. Louis, MO). 5-
hloro-Salicylaldehyde and 4-Dimethylaminobenzaldehyde were
btained from Alfa Aesar (Ward Hill, MA), and Naphthalene-2,3-
icarboxaldehyde was obtained from Santa Cruz Biotechnology
Santa Cruz, CA). Dimethyl Sulfoxide (>99.9%) was obtained from
lfa Aesar (Ward Hill, MA), and Acetonitrile, HPLC grade was  from
MD  Chemicals (Darmstadt, Germany). Methanol, HPLC grade was
btained from Burdick & Jackson (Morristown, NJ). De-ionized
ater was from an in-house Milli-Q water puriﬁcation system
Millipore, Billerica, MA). All experimental compounds and drug
amples were produced in-house at Genentech. GEN1 molecular
eight is ∼650 g mol−1 and pKa ∼6.0, while GNE2 molecular
eight is ∼200 g mol−1 and pKa ∼12. GNE1 is very hydrophobic
hile GNE2 is more hydrophilic, with the solubility of GEN2 in
ater is 10 times higher than that of GNE1.
.2. Equipment
HPLC analysis was conducted on an Agilent 1290 Inﬁnity Series
PLC-DAD system (Santa Clara, CA) equipped with a G4226A
290 autosampler, G4220A 1290 binary pump, G1316C 1290 ther-
ostatted column compartment, and G4212A 1290 photodiode
rray. An Eclipse XDB-C18 HPLC column (3.5 m,  3.0 × 150 mm)
rom Agilent (Santa Clara, CA) was used for the analysis. A Met-
ler Toledo XP 205 Micro Balance (Columbus, OH), 8510 Branson
onicator (Danbury, CT), and VWR  Dyla-Dual Hot Plate/Stirrer
Bridgeport, NJ) were also used for the sample preparation and the
erivatization reaction.
.3. Sample preparation and derivatization reaction
For the derivatization screening experiments, each reagent was
repared at a 0.1 mg/mL  concentration in DMSO. To each solution,
 hydrazine spike was added to make a 200 g/mL hydrazine ﬁnal
oncentration standard solution. The 4-Hydroxybenzaldehyde was
onicated for 30 min  at room temp. The 5-Chloro-Salicylaldehyde,
-Fluoro-2,3-Thiophenedicarboxaldehyde, and Naphthalene-2,3-
icarboxaldehyde reactions was sonicated for 20 min  at room
emperature. The 4-dimethylaminobenzaldehyde, 2-Hydroxy-1-
aphthaldehyde, and 4-Hydroxylbenzaldehyde reactions were
onicated for 30 min  at room temperature. Samples were removed
nd directly injected onto the HPLC system.iomedical Analysis 126 (2016) 141–147 143
For the ﬁnalized method conditions, a diluent solution was  ﬁrst
prepared by adding 10 mg  of derivatization reagent 2-Hydroxy-1-
Naphthaldehyde (HNA) into 100 mL  DMSO.  This diluent solution
was then used to prepare the API drug sample. Sample Solution was
prepared by adding 20 mg  drug material into a 10 mL  volumetric
ﬂask, diluted with sample diluent to volume. The ﬂask was then
sealed with glass stopper, incubated at 100 ◦C in a water bath for
30 min  for the derivatization to proceed through to completion.
Samples were aliquotted out and directed injected onto the HPLC
system.
2.3.1. Method validation
Samples of hydrazine in DMSO were prepared at 2, 4, 10, 20, 40,
100, 200 g/L concentrations for the linearity and range determina-
tion. For the LOQ, sample at a concentration of 2 g/L was  prepared
in DMSO and measured for 6 replicated injections to determine the
average signal-to-noise ratio of the lowest concentration.
Accuracy and precision experiments consisted of 6 replicates
for 1 ppm (g/g) hydrazine concentration and 3 replicates for 10
and 100 ppm (ug/g) in 2 mg/mL  pharmaceutical compounds GNE1
and GNE2. Unspiked preparations of the pharmaceutical materials
were used as a control to determine the speciﬁcity of the method.
3. Results and discussion
3.1. Derivatization reagent screening and optimization
The selection of a suitable derivatization agent is
key to designing this method for hydrazine analysis.
To evaluate the sensitivity, selectivity, reaction con-
ditions, efﬁciency, cost and commercial availability,
six derivatizing agents, 4-Dimethylaminobenzaldehyde,
4-Hydroxybenzaldehyde, 5-Chloro-Salicylaldehyde, 5-Fluoro-2,3-
Thiophenedicarboxaldehyde, Naphthalene-2,3-Dicarboxaldehyde,
and 2-Hydroxy-1-Naphthaldehyde were screened. Table 1 sum-
marizes the results of the derivatization agent screening. As
mentioned previously, the derivatization agent should maximize
conversion of free hydrazine to the derivatized hydrazone with
high selectivity. More importantly, the derivatized hydrazone
product should have a strong UV maximum that is well shifted
away from conventional 190–380 nm wavelengths of drug sample
matrix absorption and meet our chromatography needs as well.
Clearly, the 2-Hydroxy-1-Naphthaldehyde (HNA) derivatized
hydrazone product stands out given that it exhibits the largest
shift in UV maxima, at 406 nm,  which is away from the matrix
interferences of the API and well into the visible spectrum range.
This shift can be attributed to a signiﬁcantly higher degree of
conjugation, which generates a much stronger chromaphore in the
derivatized product as compared to the other tested derivatization
products. To reinforce this point, the UV absorbance spectrum of
the derivatized HNA-hydrazone product seen in Fig. 1 shows mul-
tiple UV maxima at 406 and 424 nm that had molar absorptivities
of 2.8 × 104 and 2.3 × 104 L Mol−1 cm−1, respectively. Also in terms
of the chromatography, the HNA-hydrazine reaction is the best
choice because the resultant hydrazone product is hydrophobic
and can be strongly retained on reversed-phase LC, a point we will
further discuss later in this paper. HNA is also reasonably priced
and a commercially-available reagent considering the fact that this
method will be used repeatedly for multiple batch analysis across
multiple manufacturing sites worldwide.
Fig. 2 illustrates the proposed reaction of two HNA molecules
to one hydrazine molecule to form a 2,2′-dihydroxy-1-
Naphthaldazine or hydrazone product [30]. Dimethyl Sulfoxide
(DMSO) served as an excellent strong solvent to dissolve the
pharmaceutical compounds, derivatizing reagent HNA, and yellow
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Fig. 1. UV absorbance spectrum of the HNA derivatized product showing a maxima
at  406 nm.
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Fig. 3. Derivatization optimization experiments where (A) Temperature/Solvent pH
study performed concurrently using incremental amounts of acetic acid in DMSO.
Basic pHs were achieved using sodium acetate (NaOAc) and trimethylamine (TEA)
in  DMSO. (B) Reaction kinetics study where temperature was set constant at 100 ◦C.
(C)  Reagent concentration with increasing quantities of mole to hydrazine at 100 ◦C.Fig. 2. Reaction scheme of 2-Hydroxy-1-Naphthaldehyde with hydrazine.
erivatized product. After selecting HNA as the derivatization
eagent, the reaction was optimized to ensure maximum con-
ersion of hydrazine. A number of reaction conditions, such as
H, reaction temperature, reaction time, and the mole ratio of
NA/hydrazine, were optimized through separate studies, the
esults of which are collectively summarized in Fig. 3. Fig. 3a shows
he effect of pH and temperature on the derivatization reaction
here there was no observable difference in reaction efﬁciency
etween acidic pHs (achieved by spiking 0.5 mM and 0.1 mM acetic
cid in DMSO) and blank DMSO. However, basic pHs of 8.3 and
.3 had a detrimental effect on the reaction efﬁciency; therefore,
lank DMSO with no additive was chosen as the diluent solvent. In
ddition, increased temperatures at 100 ◦C facilitated the reaction
n forming the derivatized hydrazone product. Reaction kinetics
t 100 ◦C was monitored from 15 min  to 4 h. (Fig. 3b) showing
hat 20 min  was  sufﬁcient to reach completion of the reaction.
he mole ratio of HNA/hydrazine was also optimized to ensure
he derivatizing agent is in excess to hydrazine. Fig. 3c shows that
he percent difference of the hydrazone peak response within
 range of 2:1 to 22:1 molar ratio of HNA/hydrazine was less
han 2%. The excess amount of HNA in solution did not interfere
ith the chromatography and analysis of hydrazine. Additionally,
olution stability of the reaction product was assessed where three
eplicate derivatization preps showed ≤1.0% difference over a
 day period stored in ambient room temperature. Based on these
tudies, the optimal reaction conditions were chosen to be 100 ◦C
n a water bath for 30 min  using 0.1 mg/mL  of HNA in DMSO as the
erivatizing solution.
.2. HPLC method development
A reversed-phase LC method was developed to resolve and
nalyze the derivatized hydrazone product. A number of columns
ith different stationary phase chemistries were screened in the
ethod development process such as Acentis Express C18, Waters
ymmetry C18, Xbridge Phenyl, Xselect Phenyl-hexyl, Zorbax SB-
q, and Zorbax Eclipse XDB-C18 (data not shown). As mentioned
reviously, the ideal scenario for the chromatography is whereFig. 4. Chromatogram overlay showing speciﬁcity of the derivatized HNA-
hydrazone product and its separation from the pharmaceutical material matrix
components.
the API matrix components elute early near the void volume and
far from the derivatized hydrazone product. The Zorbax Eclipse
XDB-C18 was  selected because it achieved the strongest reten-
tion of the hydrazone product and highest resolution from the
API matrix components as seen in Fig. 4. This can be attributed
to the addition of two hydrophobic, conjugated moieties onto the
hydrazine molecule, which signiﬁcantly increases its retention on
a C18 column and is ideal for separation from the more polar API
matrix components. It is also important to note that the Zorbax
Eclipse XDB-C18 column was chosen over the Waters Symmetry
C18 column because of a more stable baseline. The peak shape
and resolution of the hydrazone product was excellent with this
column.
The ﬁnalized reversed-phase LC method was  developed to ana-
lyze the derivatized hydrazone from drug API samples. A 0.05% TFA
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Table  2
Summary of ﬁnal HPLC method.
Parameters Conditions
HPLC Column Eclipse XDB-C18, 3.5 m,  3.0 × 150 mm
Mobile Phase A: 0.05% TFA in water
B: 0.05% TFA in
Acetonitrile
Injection Volume 10 L
Column Temperature 30 ◦C
Gradient Time (min) % B
0  50
5  90
10 90
Flow Rate 1.0 mL/min
UV Wavelength 406 nm
6.
95
6
P
ea
k 
A
re
a 
(A
U
)
0.0000
0.0002
0.0004
0.0006
Time (min)
6.60 6.70 6.80 6.90 7.00 7.10 7.20 7.30
6.
96
1
P
ea
k 
A
re
a 
(A
U
)
0.0000
0.0002
0.0004
Time (min)
6.60 6.70 6.80 6.90 7.00 7.10 7.20 7.30
0.0006
LOD  - 0.25 pp m (w/w) 
LOQ - 1 pp m (w/w) 
F
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0.000
0.002
0.004
0.006
Time (min)
3.00 4.00 5.00 6.00 7.00 8.00
HNA Hydrazone
GNE1 + 10 ppm Hydrazine
GNE1 + 1 ppm Hydrazine
GNE1
A.)
(A
U
)
P
ea
kA
re
a
0.000
0.002
0.00
0.006
Time ( min)
3.00 4.00 5.00 6.00 7.00 8.00
GNE2 + 10 ppm 
GNE2 + 1 ppm 
GNE2
Hydrazone
HNA
B.)ig. 5. Magniﬁed-view of hydrazone standard peaks at the LOD (0.5 g/L or
.25 ppm (w/w) in 2 mg/mL  API) and LOQ (2 g/L or 1 ppm (w/w) in 2 mg/mL  API)
evels.
n water solution was used for mobile phase A (MPA), while 0.05%
FA in acetonitrile was used for mobile phase B (MPB). A ﬂow rate
f 1 mL/min was used with an injection volume of 10 L while the
olumn temperature was maintained at 30 ◦C. For the ﬁnal method,
 UV detection wavelength of 406 nm was selected for detection of
erivatized hydrazone. Total run time was 10 min. The binary gra-
ient started with MPB  at 50% the gradient was increased to 90%
PB  in 5 min. A wash step was added after the gradient for 5 min  at
0% MPB, and then re-equilibrated at 50% MPB  for 5 min. The HPLC
ethod parameters are summarized in Table 2.
.3. Sensitivity
The method was evaluated for its limit of detection (LOD) based
n a signal-to-noise (S/N) ratio ≥3 and was determined to be
.5 g/L, which is equivalent to 250 ppb (w/w) of hydrazine in a
 mg/mL  solution of pharmaceutical material. The limit of quantiﬁ-
ation (LOQ) was based on a signal-to-noise (S/N) ratio ≥10 and
etermined to be 2 g/L, which is equivalent to 1 ppm (w/w)  of
ydrazine in 2 mg/mL  of pharmaceutical material (shown in Fig. 5).
his LOQ is adequate to quantify trace hydrazine at the limits out-
ined by ICH and regulatory health guidelines [10]. Notably, the high
ethod sensitivity reported from this work convincingly demon-
trates the advantages of three previously discussed strategies to
educe matrix interferences. The derivatization reaction serves toFig. 6. Chromatogram overlays showing derivatized pharmaceutical compound
with no hydrazine spiked, 1 ppm hydrazine spike, and 10 ppm hydrazine spike for
both (A) GNE1 and (B) GNE2.
shift the UV maxima of the derivatization product away from 190 to
380 nm by increasing its pi-pi conjugation through aromatic rings
and thus increase its molar extinction coefﬁcient. The derivatiza-
tion reaction also gives greater selectivity from a chromatography
standpoint on a C18 reversed phase column, which allows for the
derivatization product to be well separated from the API matrix
components. Additionally, the method was  performed using UV
detection, an attractive beneﬁt when considering its ease of use in
a Good Manufacturing Practice (GMP) setting and ease of method
transfer across external GMP  facilities.
3.4. Method validation results
The method was  then validated for its speciﬁcity, linearity and
range, accuracy, and precision to demonstrate that the method is
suitable for its intended use per ICH Q2(R1) guideline [32]. The full
results of the method validation experiments are summarized in
Table 3.
The speciﬁcity of this method was  demonstrated by separa-
tion of two GNE drug compounds. The resolution of the hydrazone
derivative from other matrix components is greater than 2.5. The
representative chromatograms were showed in Fig. 4.
The method exhibits good linearity and range with a lin-
ear regression ﬁt of R2 = 1.000 with a best ﬁt equation of
y = 0.54x − 0.21. The method has been demonstrated to be linear in
a range of at least two orders of magnitude from 2 g/L to 200 g/L.
The detection and quantitation limits were validated based on
an S/N ratio of ≥3 and 10, respectively. The limit of detection of
0.5 g/L showed an S/N ratio range from 3 to 4, while a range of
11–20 of S/N ratio was observed for quantitation limit of 2 g/L,
of which the percent of relative standard deviation (RSD) of peak
area was  7.0% for six replicate injections. The quantitation limit
was also validated with sample matrix where 2 g/L of hydrazine
was spiked in 2 mg/mL  concentration of drug material, which is
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Table 3
Summary of method validation data.
Parameter Experiment Results
Linearity Hydrazine standard at 7 levels: 2, 4, 10, 20, 40, 100,
200 g/L
Correlation coefﬁcient, R2 = 1.00, Slope = 0.54,
Intercept = −0.21
Speciﬁcity Method Blank, 2 GNE compounds and spiked compounds
with hydrazine
Absent target peak from blank, The resolution of the target
and closest peak is more than 2.5
Detection limit 6 replicated injection of 0.5 g/L hydrazine standard Signal-to-noise ratio was 3, 4, 4, 5, 3, 3
Limit  of Quantitation 6 replicated injection of 2 g/L hydrazine standard Signal-to-noise ratio was 11, 12, 12, 20, 11, 12 %RSD of
peak area is 7.0%
Accuracy/Precision 6 replicate sample solutions (2 mg/mL) were spiked with
hydrazine at 1 ppm 3 replicate sample solutions (2 mg/mL)
were spiked with hydrazine at 10 and 100 ppm
Solution Stability Spiked sample solutions were stored at ambient conditions The %change in assay at t3 day was less than 1.0% from
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[for 3 days
quivalent to 1 ppm (w/w) of hydrazine. The average percent of
ecovery of six replicate injections at this level is 97.1% with a %RSD
f 2.4%.
Accuracy and precision was validated on a pharmaceutical drug
aterial spiked with hydrazine at three concentration levels cov-
ring the speciﬁed range with 6 replicates for 1 ppm hydrazine
oncentration and 3 replicates for 10 and 100 ppm. The pharma-
eutical material was prepared at a concentration of 2 mg/mL. The
ercent recovery was calculated by the assay of spiked hydrazine
n drug materials. The individual percent recoveries for all prepa-
ations were from 94.6–101.2% and the %RSD for all injections was
.3%.
The developed hydrazine method was tested on a pharma-
eutical drug substance GNE1 and a pharmaceutical intermediate
ompound GNE2. The samples were taken and subjected to the
erivatization reaction; spiked sample solutions of 1 ppm and
0 ppm also were prepared and measured. Fig. 6 shows the chro-
atogram overlay of these experiments where the GNE compounds
ithout hydrazine spiked were compared against 1 ppm and
0 ppm (w/w) spiked samples demonstrating that hydrazine was
etected and accurately quantiﬁed.
. Conclusion
We  have developed a method for the sensitive and accu-
ate quantitation of hydrazine in pharmaceutical materials using
 simple derivatization reaction and RPLC-UV. Selection of the
erivatization agent, 2-Hydroxy-1-Naphthaldehyde, was a key step
oward this analytical approach, which generates a derivatized
roduct that meets the speciﬁc requirements of our analyti-
al strategies. The derivatization effectively shifts the resultant
ydrazone product away to higher wavelengths in the UV spec-
rum where API matrix components do not interfere with the
nalysis. Secondly, the derivatization reaction generates a prod-
ct that can be separated on a reversed-phase LC method with
igh resolution from the rest of the API matrix. A speciﬁc LC-
V method using an Eclipse XDB-C18 column was tailored to
chieve the desired chromatography with the HNA-hydrazone
roduct and was demonstrated for suitable speciﬁcity, linear-
ty/range, accuracy and precision. The LOQ of the method was
etermined to be 1 ppm (w/w) based on the average signal-to-noise
atio of 6 replicate injections of a 2 mg/mL  API and was  ade-
uate for sensitive quantiﬁcation of hydrazine in pharmaceutical
aterials.
[initial t0 day
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